A Phase II Study of Nivolumab plus Ipilimumab in advanced HCC patients who have progressed on first-line Atezolizumab + Bevacizumab

A Phase II Study of Nivolumab + Ipilimumab in Advanced HCC Patients Who Have Progressed on First Line Atezolizumab + Bevacizumab »